Citadel Advisors’s Apollo Endosurgery, Inc. APEN Stock Holding History

Citadel Advisors’s Portfolio APEN Stock Details APEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-700	Closed	-$6.98K	–	16001
2022 Q4	$6.98K	Sell	700 -14,400	-95%	-$107K	﹤0.01%	13865
2022 Q3	$83K	Buy	+15,100	New	+$83.7K	﹤0.01%	11253
2021 Q4	–	Sell	-10,400	Closed	-$94K	–	15175
2021 Q3	$94K	Sell	10,400 -2,200	-17%	-$18.9K	﹤0.01%	12947
2021 Q2	$102K	Buy	12,600 +200	+2%	+$1.37K	﹤0.01%	12911
2021 Q1	$68K	Buy	+12,400	New	+$61.3K	﹤0.01%	12756

Citadel Advisors's APEN Position: Q2 2023 in Review

Citadel Advisors sold out of Apollo Endosurgery, Inc. (APEN) in Q2 2023, closing a stake of 13,615 shares — an estimated $135K sold.

Citadel Advisors first reported a position in APEN in Q3 2015 and held it in 13 quarters. The position peaked at $619K in Q4 2021. 0 funds tracked by Wall St. Rank hold APEN as of Q2 2023.

Citadel Advisors reported no remaining Apollo Endosurgery, Inc. position as of Q2 2023 after selling out during the quarter.
Citadel Advisors sold 13,615 Apollo Endosurgery, Inc. shares in Q2 2023, an estimated $135K.
Citadel Advisors first reported a position in Apollo Endosurgery, Inc. in Q3 2015 and held it in 13 quarters.
Citadel Advisors's Apollo Endosurgery, Inc. position peaked at $619K in Q4 2021.
0 funds tracked by Wall St. Rank held Apollo Endosurgery, Inc. as of Q2 2023.

Based on Citadel Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.